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Abstract
Background & Aims—Studies of hepatitis C virus (HCV) infection, immunopathogenesis, and
resulting liver diseases have been hampered by the lack of a small animal model. We developed
humanized mice with human immune system and liver tissues to improve the studies of hepatitis C
pathogenesis and treatment.
Methods—To promote engraftment of human hepatocytes, we expressed a fusion protein of the
FK506 binding protein (FKBP) and caspase 8 under control of the albumin promoter (AFC8),
which induces liver cell death, in Balb/C Rag2-/- γC-null mice. Co-transplantation of human
CD34+ human hematopoietic stem cells (HSC) and hepatocyte progenitors into the transgenic
mice led to efficient engraftment of human leukocytes and hepatocytes. We then infected these
humanized mice (AFC8-hu HSC/Hep) with primary HCV isolates and studied HCV-induced
immune responses and liver diseases.
Results—HCV-infected livers of AFC8-hu HSC/Hep mice generated a human immune T-cell
response against HCV. HCV infection induced liver inflammation, hepatitis, and fibrosis, which
correlated with activation of stellate cells and expression of human fibrogenic genes.
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Conclusions—AFC8-hu HSC/Hep mice are a useful model of HCV infection, the immune
response, and liver disease, because they contain human immune system and liver cells. These
mice become infected with HCV, generate a specific immune response against the virus, and
develop liver diseases that include hepatitis and fibrosis. This model might also be used to develop
therapeutics for HCV infection.
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Introduction
Over 175 million people are chronically infected by hepatitis C virus (HCV), often resulting
in hepatitis, liver fibrosis, cirrhosis and development of hepatocellular carcinoma (HCC)1.
The liver consists of unique subsets of antigen presenting cells and lymphocytes2, 3. It is
postulated that HCV infection in the liver leads to impaired immune response that
contributes to its chronic infection in 80% of infected patients. Chronic inflammation and
impaired T cell responses in the liver are proposed to lead to liver disease4-7. Due to the
difficulty of studying HCV infection in human patients, very little is known about how HCV
infects patients and evades host immunity to establish chronic infection in the liver.
HCV infection triggers robust CD4 and CD8 cytotoxic T cell (CTL) responses in infected
patients. However, the majority of HCV patients fail to resolve HCV infection and become
chronically infected, associated with impaired CD4 and CD8 T cell functions4, 7. Sustained
CD4+ T helper activity in the blood is a hallmark of infections that are cleared
spontaneously in 10-20% of HCV-infected patients4, 6, 8. While chimpanzees that resolve
infection have strong CTL response, those with chronic infection show reduced CTL
response8, 9. The CTL response in chronically infected HCV patients is also reduced8, 10, 11.
During chronic HCV infection in humans and chimps, regulatory T cells (Treg) are also
induced to subdue the anti-viral immune responses12, 13. Thus, both CD4 and CD8 T cells
are involved in HCV immunopathogenesis. However, we understand very little of human
immune response to HCV infection, due to lack of a robust model to study HCV infection
and immuno-pathogenesis14.
Although chimpanzees have played a critical role in studying HCV infection15, there are
several drawbacks, including low chronic infection rate and lack of liver fibrosis, as well as
costs and ethical concerns, that limit their utility. A mouse engrafted with human liver cells
and a functional human immune system will be an excellent model to study the virus14. A
number of human-mouse chimeric liver models have been developed, but allow analyses of
only limited aspects of HCV infection and pathogenesis16, 17. The Alb-uPA/SCID
transgenic mouse contains the uPA transgene under control of an albumin promoter, and
homozygous animals are unhealthy and die due to profound hypo-fibrinogenemia and
accelerated hepatocyte death, which can be rescued by transplantation of mouse or human
hepatocytes17, 18. The Alb-uPA/SCID mouse with efficient human hepatocyte engraftment
can be infected with HCV17. It is reported recently that Fah-Rag2- γC-null mouse can also
be highly engrafted with human hepatocytes to support HCV infection19-21. However, due
to lack of a functional immune system, it is not possible to study HCV immuno-
pathogenesis and no liver diseases are observed in Alb-uPA/SCID or Fah-Rag2-γC-null
model17, 21.
The Balb/C Rag2-γC-null mouse supports development of a functional human immune
system after injecting CD34+ human hematopoietic stem cells (HSC)22. To facilitate
engraftment of human liver cells in Balb/C Rag2-γC-null mice, we expressed the active
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Caspase 8 fused with FK506 binding domain (FKBP) with inducible suicidal activity23. We
co-transplanted human hepatocyte progenitor cells and CD34+ HSC into the transgenic mice
and treated them with the FKBP dimerizer. Human immune cells and human hepatocytes
were both efficiently developed, thereby generating a mouse model containing both a human
immune system and human liver cells (AFC8-hu HSC/Hep). AFC8-hu HSC/Hep mice
supported HCV infection in the liver and generated human T cell response to HCV. In
addition, HCV infection induced liver inflammation and fibrosis, correlated with activation
of stellate cells and expression of human fibrogenic genes.
Results
AFC8 mice can be efficiently repopulated with both human liver and immune cells
We constructed the FKBP-Caspase 8 fusion gene23 driven by the albumin enhancer/
promoter (AFC8 gene)24. Dimerization of the active Caspase 8 by AP20187 induced
apoptosis of cells in which it is expressed but not of bystander cells (Fig. 1A and
Supplementary Figure 1). We then generated transgenic Balb/C Rag2-γC-null mice with the
AFC8 transgene, and confirmed the liver-specific expression of the AFC8 transgene
(Supplementary Figure 2).
When AFC8+ mice were treated with AP20187, we observed a repeated induction of ALT
in AFC8 mice but not in littermate control mice (Figure 1B). To test the ability of the AFC8
mice to engraft human hepatocytes as well as human immune cells, human CD34+ cells
(HSC) and hepatocyte progenitor cells (Hep) from the same human fetal liver tissue were
injected into the liver of irradiated newborn AFC8 mice. We observed a significant increase
of human albumin+ hepatocytes in the AFC8-hu chimeric liver (Figure 1C). About 15%
(n>10 mice) of total nucleated cells in the chimeric liver expressed human albumin in
AFC8-hu HSC/Hep mice from multiple human fetal liver tissues between 5-16 weeks post
transplant (Figure 1D and Table 1). Using human gene-specific PCR primers
(Supplementary Figure 3A), we also detected expression of human albumin and human
hepatocyte genes CYP2E1, CYP2C9 and UGT2B7 in the liver of AFC8-hu HSC/Hep mice
(Supplementary Figure 3B). As expected, AFC8-hu HSC/Hep mice also generated human
immune cells in all lymphoid organs including the liver (Supplementary Figure 4 and data
not shown). Therefore, we established a humanized mouse model with both human immune
and human liver cells.
HCV infection leads to liver infiltration and hepatitis in AFC8-hu HSC/Hep mice
We inoculated AFC8-hu mice with patient HCV isolates (genotype 1a) or control human
serum (Table 2). We detected HCV genomic RNA in the liver of about 50% HCV-infected
AFC8-hu mice (Figure 2A and Table 2) at termination (1-4 months post infection), but were
unable to detect HCV viremia in the blood of infected mice (data not shown). As controls,
we did not detect HCV RNA in mock-infected AFC8-hu HSC/Hep mice or in HCV-infected
AFC8 mice with no human cell transplant (Figure 2A).
When ALT levels were measured at various times after HCV infection, significant induction
of ALT was detected in HCV-infected AFC8-hu mice after 2-4 weeks post infection, but not
in control mice (Figure 2B). Consistent with elevated ALT levels, we observed significant
leukocyte infiltration into the liver in HCV infected AFC8-hu HSC/Hep mice (Figure 2C).
We observed an increase of human CD45+ leukocyte, including CD68+ macrophages and
CD3+ T cells, in the liver of HCV infected mice (Figure 2C lower panel and Supplementary
Figure 5A). When total intrahepatic leukocytes were analyzed, we detected an increase of
multiple human leukocyte subsets including CD3+CD4+ and CD3+CD8+ T cells, CD3-
CD56+ natural killer cells, and plasmacytoid dendritic cells (pDC, CD123+CD4+CD3-) in
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the liver of HCV infected mice (Supplementary Figure 5B). Similar infiltrations have been
reported in HCV-infected humans25-27. Thus AFC8-hu HSC/Hep mice were able to support
HCV infection in the liver, leading to liver infiltration and injury.
HCV infection induces HCV-specific human T cell immune response
To characterize the human T cell response in HCV-infected AFC8-hu HSC/Hep mice, we
stimulated (PHA for 12 hrs) spleen and lymph nodes (LN) cells from mock- or HCV-
infected mice and measured human effector cytokines (IL2, IFNγ, and TNFα) in human
CD4+ and CD8+ T cells. We observed a significant increase of all three cytokines in both
CD4+ (Figure 3A,B) and CD8+ (Figure 3C) T cells from HCV-infected AFC8-hu HSC/Hep
mice. Therefore, HCV infection primed human T cells in AFC8-hu HSC/Hep mice.
To detect HCV-specific T cell response, we stimulated the spleen/LN cells from mock and
HCV infected mice with an overlapping peptide pool from the HCV core region in the
presence of anti-CD28 mAb. After 8-10 days in culture, we observed a 4-5 fold preferential
expansion of human CD3+ T cells from HCV-infected mice relative to mock control mice
(Figure 4A). When restimulated with HCV core peptides, both human CD4+ (Figure 4B,C)
and CD8+ (Figure 4D,E) T cells from HCV-infected mice also responded to produce IFNγ,
IL2 and TNFα. Thus HCV infection in AFC8-hu HSC/Hep mice induced specific human T
cell response to HCV antigens.
AFC8-hu HSC/Hep mice develop liver fibrosis after HCV infection
We then assessed liver pathology in HCV-infected AFC8-hu HSC/Hep mice. About 50% of
HCV-infected AFC8-hu HSC/Hep mice had severe fibrosis throughout the liver parenchyma
(Figure 5A, top panels and Table2), whereas mock-inoculated AFC8-hu HSC/Hep mice and
HCV-inoculated AFC8 mice without human transplants did not develop fibrosis. Infiltrated
human CD45+ cells in the liver were detected in the fibrotic regions (Figure 2). In the
absence of a functional immune system, uPA/SCID or Fah-Rag-γC-null mice transplanted
with only human hepatocytes supported HCV infection but no significant liver fibrosis17, 21.
We analyzed HCV infection and liver pathology in five AFC8-hu mice transplanted with
only human adult hepatocytes, and did not detect significant liver fibrosis (Table 2). The two
AFC8-hu Hep mice with low-grade fibrosis were analyzed 12-24 hrs after unexpected death.
In human patients, HCV infection leads to activation of hepatic stellate cells, which
contributes to liver fibrosis28. We stained liver sections with the mouse anti-human α-
smooth muscle actin (αSMA) mAb to detect activated stellate cells. We observed activated
stellate cells in the liver of HCV-infected AFC8-hu HSC/Hep mice (Figure 5, A bottom
panels). Activated hepatic stellate cells also express extracellular matrix protein Col1A1 and
TIMP1 which inhibits degradation of extracellular matrix and fibrosis resolution29. We thus
analyzed the expression of these genes in the liver with human-specific or mouse-specific
PCR primers (Supplemental Figure 6). Interestingly, we detected specific induction of
human TIMP1 (Figure 5B) and human COL1A1 (Figure 5C), but not mouse fibrosis genes,
in the liver of some HCV-infected AFC8-hu HSC/Hep mice. These results suggest that HCV
infection activated human stellate cells and induced expression of human fibrogenic genes in
the chimeric liver of AFC8-hu HSC/Hep mice.
Discussion
We report here a novel mouse model that supports efficient engraftment of both human
immune cells and human liver cells. The Balb/C Rag2-γC-null mouse with the AFC8
transgene enabled us to inducibly deplete murine hepatocytes. In addition to human immune
cells in lymphoid and liver organs, AFC8-hu HSC/Hep mice were also efficiently
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repopulated with human albumin+ liver cells. AFC8-hu HSC/Hep mice supported HCV
infection, which induced HCV-specific human immune response, liver infiltration, hepatitis
and fibrosis.
In the absence of a functional immune system, uPA/SCID or Fah-Rag-γC-null mice
transplanted with only human hepatocytes supported HCV infection but no significant liver
fibrosis17, 21. Immuno-deficient mice expressing the uPA transgene in the liver or carrying
the Fah mutation allow human adult hepatocytes to efficiently re-populate the liver17-20.
These mice have poor health including neonatal death and, most importantly, the lack a
human immune system. The severe liver injury in these mice may impair the development
and function of human liver and immune cells. To overcome these deficiencies, the AFC8
mouse enabled us to inducibly deplete murine hepatocytes through a programmed cell death
mechanism without bystander cell killing. In addition, the Rag2-γC-null mouse in Balb/C
background permits efficient engraftment of human immune cells. Therefore, AFC8-hu
HSC/Hep mice provide the first humanized mouse model with both human immune and
liver cells.
We inoculated AFC8-hu HSC/Hep mice with HCV genotype 1a clinical isolates. We were
able to detect HCV genomic RNA in the liver of AFC8-hu HSC/Hep mice (Figure 2A and
Table 2), but we did not detect significant HCV viremia in the blood of HCV-inoculated
AFC8-hu HSC/Hep mice. This may be due to the relative low level of human hepatocyte
engraftment (∼15%). To detect HCV viremia in the blood, the adult hepatocyte-engrafted
uPA or Fah models support >50% engraftment of human hepatocytes17, 19-21. In the future
we will improve the AFC8-hu HSC/Hep model by optimizing the death induction conditions
with different doses and times of dimer injections. It is also reported that the NOD-Scid-
γC-/- (NSG) mouse is more permissive in accepting human cells30. It is likely that the
introduction of the AFC8 transgene into NSG mice will create a better host for engrafting
human immune and liver cells. To get different sources of human HSC and liver progenitor
cells, the AFC8-hu mouse model will be useful to study functional differentiation of human
embryonic stem (hES) or induced plural-potent (iPS) cells to the human liver lineages. The
construction of AFC8-hu HSC/Hep mouse with HSC and liver progenitor cells derived from
ES or iPS cells will be an exciting future direction.
HCV infection appeared to induce human immune responses in AFC8-hu SHC/Hep mice.
We observed significant infiltration into the liver of HCV-infected AFC8-hu HSC/Hep
mice, including human T cells, macrophages, DC and NK cells. Not only did we observe a
preferential expansion of human T cells from HCV-infected AFC8-hu HSC/Hep mice with
HCV-derived peptides, the expanded T cells also expressed IL2, TNFα and IFNγ in
response to HCV peptide re-stimulation (Figure 4). Therefore, HCV infection induced HCV-
specific human T cell responses in AFC8-hu HSC/Hep mice. It will be interesting to test if
depletion of human T cells (CD4 and/or CD8) will affect HCV infection and pathogenesis in
AFC-hu HSC/Hep mice. It will also be of interest to characterize and study human T cell
subsets such as regulatory T cells and NKT cells in future experiments. Consistent with poor
B cell response has been reported in all humanized mouse models, we failed to detect HCV-
specific human antibodies in HCV-infected AFC8-hu HSC/Hep mice (data not shown).
In human patients, immune responses against HCV are implicated as mediators of liver
diseases31, 32. Remarkably, HCV-infected AFC8-hu mice developed human leukocyte
infiltration, hepatitis and liver fibrosis throughout the liver parenchyma with bridging septa
(Figure 5). Human CD3+ T cells and CD68+ macrophages, as well as human albumin+
hepatocytes and αSMA+ activated stellate cells, were detected in and near the fibrotic region
(supplementary Figure 7), suggesting contribution of human leukocytes to liver fibrosis. We
also showed that HCV infection led to increased level of activated human stellate cells in
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fibrotic livers. Human extracellular matrix protein Col1A1 and inhibitor of matrix
degradation TIMP1 were induced in HCV-infected AFC8-hu HSC/Hep mouse livers. It is of
interest that the corresponding mouse fibrosis-associated genes were not induced by HCV
infection. The lack of liver fibrosis in chronically infected chimpanzees also suggests a
species-specific nature of HCV-induced liver fibrosis33. The AFC8-hu HSC/Hep mouse will
provide an excellent model to elucidate the mechanisms of HCV-induced human liver
fibrosis.
Since HIV co-infection occurs in nearly 25% of HCV patients and often leads to accelerated
end-stage liver disease32, 34, 35, there is a significant need for a model system to study HCV/
HIV co-infection. It will be of interest to test how HIV-1 infection will affect HCV infection
and pathogenesis in the AFC8-hu HSC/Hep mouse. In addition to HCV infection and
immuno-pathogenesis, AFC8-hu HSC/Hep mice will also be useful to study other liver-
tropic pathogens such as HBV and malaria.
Methods
Plasmids
The FKBP-Caspase 8 gene was generated by cloning active human Caspase 8 (fragment
Ser217-Asp479, kindly provided by Dr. Terry Combs, UNC-Chapel Hill) into the pC4M-
Fv2E vector (Ariad Pharmaceuticals) to express the FKBP-Caspase 8 (FC8) fusion
protein23. The transgenic construct was generated with the Albumin enhancer/promoter24
(kindly provided by Dr. Snorri Thorgessons, NIH) controlling expression of the FKBP-
Caspase 8 gene.
Generation of AFC8 transgenic mice
Animal procedures were obtained approved by the University of North Carolina Institutional
Animal Care and Use Committee (IACUC). Balb/C Rag2-/-γC-/- mutant female mice were
super-ovulated and the fertilized eggs were isolated to generate transgenic mice by standard
procedures in the UNC transgenic core facility. AFC8 mice were bred and handled under
specific pathogen free conditions in the UNC DLAM facility.
Induction of murine hepatocyte death in AFC8 mice
We injected mice ip or iv with AP20187 (Ariad Pharmecuticals) or vehicle only (4%
ethanol, 10% PEG-400, 2% Tween-20 in water) at a dose of 5 ug/g body weight at indicated
days post transplant of human cells23. ALT levels were measured in the blood of treated
mice.
Human hepatocyte progenitor cells and CD34+ HSC from human fetal liver
Human hepatocyte progenitor and CD34+ cells were isolated from 15-18 weeks old fetal
liver tissue essentially as described 36-38. Parenchyma cells (30% EpCAM+ hepatoblasts/
progenitors) were separated from the non-parenchyma cells (including CD34 HSC cells).
CD34+ cells were isolated by magnetic-activated cell sorting (MACS), and the purity was
greater than 95%.
Transplantation of AFC8 mice with human CD34 HSC and liver progenitor cells
CD34+ HSCs (0.5 -1×106) and Hep progenitor cells (0.5-1×106) from the same donor were
co-injected into the liver of 1 to 5 days old newborn AFC8 and littermate control mice,
previously irradiated at 400 rad36, 38. We then injected AFC8-hu mice with AP20187 (Ariad
Pharmecuticals) at a dose of 5ug/g body weight as described above.
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Blood and tissue analysis
AFC8-hu HSC/Hep mice were bled to measure human leukocyte reconstitution at 12-16
weeks post transplant. At termination, liver tissue was snap-frozen in RNAlater (Qiagen) or
fixed in 10% formalin. Liver sections were stained with hematoxylin and eosin (H&E),
Sirius Red and Fast Green, or with antibodies: mouse monoclonal anti-human α smooth
muscle actin (1A4, Dako), mouse monoclonal anti-human CD45 (2B11 + PD7/26, Dako),
and anti-human albumin (Dako). Immunoreactivity was determined by incubation with DAB
substrate (Pierce) or Vulcan red (Dako), and counterstained with hematoxilin36, 38.
Human-specific gene expression
Human or mouse specific quantitative real time PCR primers were designed using NCBI
primer design program and Blast database (see supplemental Figures 3 & 6). Gene
expression analysis was examined using Thermo Scientific SYBR Green Realtime PCR
reagents. Values shown are relative gene expression normalized to specific GAPDH.
HCV infection of AFC8-hu HSC/Hep mice
AFC8-hu HSC/Hep mice or control mice were inoculated iv with 100ul of clinical isolates
of HCV genotype 1a (1∼5×107 genome copies/ml) or control human sera. Mouse blood and
liver tissues were harvested to prepare RNA for measuring HCV genomic RNA as
reported39.
T cell response analysis
Leukocytes from various tissues of AFC8-hu mice were analyzed by FACS for human
surface markers. Total spleens and lymph node cells containing 1 × 105 human CD45+ cells
were stimulated for 20 hours with 10ug/ml PHA in IMDM + 10% FBS media (Gibco). The
cells were then stained for human T cells (CD45, CD3, CD4, CD8), and for intracellular
human IL-2, TNF-α, and IFN-γ. To detect HCV-specific human T cell response, human T
cells were expanded by stimulating spleen/LN cells with a pool of 19 HCV core peptides
(20mer overlapping by 10) at 10ug/ml each + 1ug/ml anti-CD28 mAb. The cells were then
cultured for 8-10 days with expansion medium (IMDM, 10% FBS, 10U/mL human IL-2 and
125ng/mL IL-7). The cells were re-stimulated with the same HCV core peptide pool for 18
hours and stained as above.
Statistical analysis
We used unpaired two-tailed Student's t-tests for all comparisons. p<0.05 is considered
significant. All data are reported as means ± standard deviation (s.d.) or standard error
(s.e.m) as indicated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
HCV Hepatitis C Virus
HSC hematopoietic stem cells




TIMP1 tissue inhibitor of matrix metalloproteinases 1
Col1A1 Collagen 1A1
NK natural killer cells
pDC plasmacytoid dendritic cells
PHA phytohaemagglutinin
Treg regulatory T cells
uPA urokinase-type plasminogen activator
Fah fumarylacetoacetate hydrolase
AFC8 FKBP-Caspase 8 gene driven by the albumin promoter
AFC8-hu HSC/Hep AFC8 transgenic mouse transplanted with human CD34+
hematopoietic stem cells and hepatocyte progenitor cells
αSMA α-smooth muscle actin
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Figure 1. AFC8 mice support engraftment of human hepatocytes in the liver
(A) Inducible activation of Caspase 8 through dimerization of FKBP-Caspase 8. The
chemical dimerizer AP20187 leads to activation of Caspase 8 and apoptosis. (B) Mouse
liver injury can be repeatedly induced in AFC8 transgenic mice. AFC8 or littermate control
mice (4-6 weeks old) were injected with AP20187 at day 0 and day 6. ALT was measured in
serum at -1, 0, 1, 3, 6 and 7 days post-drug treatment. Data are representative of three
experiments with n = 4 per group. Data represent means ± s.d. *, P < .05. (C) Liver sections
from control mice without transplant (left) and both control (middle) and AFC8 (right)
transplanted with human HSC/Hep (AFC8-hu HSC/Hep) were stained with anti-human
albumin antibody. Human hepatocytes were present around the veins and dispersed
throughout all lobes of the liver. (D) Human albumin positive cells and total nucleated cells
in the liver of humanized AFC8 and non-transgenic littermate control mice were counted
and the percentage of Alb+ positive cells was calculated (n = 16 mice per group, **, P < .
01).
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Figure 2. HCV infection in AFC8-hu HSC/Hep mice leads to human immune infiltration and
liver injury
AFC8-hu HSC/Hep mice or control mice were infected with HCV patient isolates (genotype
1a, 1×10e5 i.u./mouse) or control serum. Blood samples were collected at various times after
infection. Liver samples were collected at termination time points. (A) HCV genomic RNA
was detected in the liver of HCV-infected AFC8-hu mice. Liver tissues were harvested from
HCV-infected AFC8-hu or control mice at 70-80 days post-infection. Values represent HCV
RNA copy#/ug liver-derived RNA in triplicates. * P <.05. (B) Increased ALT in sera from
HCV-infected AFC8-hu or control mice. Data represent mean ± s.e.m (n = 6 mice per
group). *, P < .05. (C) Representative liver sections from control/mock, AFC8-hu/mock,
control (no transplant)/HCV, and two AFC8-hu/HCV mice were stained to detect leukocyte
infiltration with H&E (top panels), or with anti-human CD45 (middle panels) or human
CD68 (bottom panels).
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Figure 3. HCV infection induces human T cell response in AFC8-hu mice
Spleen and lymph node cells from mock- and HCV-infected AFC8-hu mice at 6-8 weeks
post infection were stimulated for 12-16 hours with PHA. Cells were stained with antibodies
for human T cells (CD3, CD4 and CD8) and for intracellular human cytokines (IL-2, IFN-γ
and TNF-α). (A) Human CD3+ CD4+ T cells were analyzed for expression of effector
cytokines. Representative FACS plots are shown for each cell population. Numbers
represent the % cytokine+ of CD4 or CD8 T cells. (B) Increase of human CD4 effector T
cells in HCV infected AFC8-hu mice. Summarized data (n=4 mice/group) are shown. (C)
Increase of human CD8 effector T cells in HCV infected AFC8-hu mice. Human CD3+
CD8+ T cells were similarly analyzed for expression of effector cytokines. Data represent
mean ± s.e.m from two cohorts of mice with n = 4 per group. *, P <.05; **, P <.01; ***, P <.
001.
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Figure 4. HCV infection induces HCV-specific human T cell response in AFC8-hu mice
(A) Preferential expansion of human T cells from HCV-infected AFC8-hu mice after
stimulation with HCV Core peptides. Spleen and LN cells from mock and HCV-infected
AFC8-hu mice were stimulated with a pool of HCV Core peptides + anti-CD28 mAb, and
cultured for 8-10 days. Fold increase of human CD45+CD3+ cells from HCV infected
samples (n=4) was calculated relative to mock samples (n=3). P <.05. (B-E) The expanded
T cells were re-stimulated with HCV peptides and stained for intracellular human cytokines
(IL-2, IFN-γ and TNF-α). (B) Human CD4+ T cells are analyzed for expression of the
cytokines. No stimulation controls show background. (C) Summarized results of individual
mice are shown. (D) Human CD8+ T cells are analyzed for expression of the cytokines.
Representative FACS plots are shown for each cell population. Numbers in FACS plots
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represent the % cytokine+ of CD4 or CD8 T cells. (E) Shown are summarized data of
individual mice from two cohorts of mice (n = 4 per group). Lines indicate the mean values.
*, P <.05; **, P <.01; ***, P < .001.
Washburn et al. Page 15













Figure 5. AFC8-hu HSC/Hep mice develop liver fibrosis after HCV infection
(A) Representative liver sections from AFC8/mock, AFC8-hu/mock, AFC8 (no transplant)/
HCV, and three AFC8-hu/HCV mice were stained with Sirius Red/Fast Green (top panels)
to visualize liver fibrosis. Liver sections were also stained with a mouse monoclonal
antibody against human α-smooth muscle actin (αSMA, bottom panels) to visualize
activated stellate cells. Human or murine specific gene expression of TIMP1 (B) and
COL1A1 (C) in the liver was measured using species-specific PCR primers. Values shown
are relative gene expression normalized to human or mouse GAPDH, respectively. Data
represent mean ± s.e.m.
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